Elucidating the possible mechanism of action of some pathogen box compounds against leishmania donovani

Medicine and Dentistry

• Cell Cycle Progression 66%
• Disease 33%
• G1 Phase 33%
• Growth Disorder 33%
• Health Care Cost 33%
• Human Immunodeficiency Virus 33%
• In Vitro 33%
• Leishmania donovani 100%
• Leishmaniasis 100%
• Lutzomyia 33%
• Lymphatic Filariasis 33%
• Macrophage 33%
• Medicine 33%
• Mitosis 33%
• Mixed Infection 33%
• Morphology 33%
• Neglected Tropical Diseases 66%
• Pathogen 100%
• Phlebotomus 33%
• Programmed Cell Death 33%
• RAW 264.7 Cell Line 33%
• Therapeutic Window 33%
• Zoonosis 33%

Immunology and Microbiology

• Amastigote 66%
• Cell Cycle G1 Phase 33%
• Cell Cycle Progression 66%
• Coinfection 33%
• Diptera 33%
• Human Immunodeficiency Virus 33%
• Infectious Agent 100%
• Leishmania donovani 100%
• Leishmaniasis 100%
• Lutzomyia 33%
• Lymphatic Filariasis 33%
• Macrophage 33%
• Mitosis 33%
• Morphology 33%
• Phlebotominae 33%
• Phlebotomus 33%
• Promastigote 66%
• Protozoa 33%
• RAW 264.7 Cell Line 33%
• Sergentomyia 33%
• Zoonosis 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Amastigote 66%
• Diptera 33%
• Disease 33%
• Growth Disorder 33%
• HIV 33%
• Infectious Agent 100%
• Leishmania donovani 100%
• Leishmaniasis 100%
• Lutzomyia 33%
• Lymphatic Filariasis 33%
• Mixed Infection 33%
• Phlebotominae 33%
• Phlebotomus 33%
• Promastigote 66%
• Protozoon 33%
• Sergentomyia 33%
• Therapeutic Window 33%
• Tropical Disease 66%
• Zoonosis 33%